AUG 10, 2019 10:20 AM PDT

Can LSD Treat Addiction?

WRITTEN BY: Annie Lennon

Modern medicine commonly refers to addiction as a brain disease caused by drugs and other negative stimuli. However, evidence is surmounting that addiction may in fact have more fundamental causes. This is bringing about rapid change in the way it may be treated- namingly, with substances previously considered dangerous and taboo such as LSD. 

Although certain drugs and substances may stimulate an addiction response, recent research indicates that it may have a more underlying cause: an inability to connect oneself to a deeper sense of meaning, value and purpose. Nowadays, rather than looking at surface factors which may simply stimulate addiction, researchers are increasingly finding that it may be a form of escapism from the pain associated with the experience of living. Thus, rather than being a pharmacological condition, addiction may indeed be an existential one (Taub: 2018). 

This is where psychedelics, such as LSD, come to the table. Known to ignite feelings of a deeper understanding of life and the world when used in controlled settings, psychedelics may be key to addressing existential questions. Their ability to provide different reference points of how reality may be, and to help people confront their fears and limiting beliefs, has been known to make people not only more at peace with any underlying trauma, but also more accepting and calm about life in general. This feeling of peace and acceptance is thus an important step towards curing addiction, as it confronts and dissolves any pain associated with living, and perhaps the addiction too (Bleyer: 2017). 

Since LSD was first synthesized, many experiments and studies have demonstrated its efficacy in treating addiction in psychotherapeutic settings. A meta-study looking at six clinical trials between 1966 and 1970, for example, found that of those who had taken LSD as part of their treatment for alcoholism, 59% decreased their alcohol consumption, compared to 38% who did not take the drug (Krebs: 2012). The study further found that participants who took LSD during their therapy were 15% more likely to remain sober six months after leaving treatment than those who did not take it (Chant: 2012).

But how did this happen? The short term effects from taking the psychedelic are known to decrease impulsivity and improve mood by downregulating the serotinin system. However, as brain imaging techniques have shown, this downregulation only lasts for a week, making it unlikely to account for long-term changes. Thus, it has been suggested that any longterm changes from the drug may be caused neuronal changes that essentially cause a remodeling of the brain that unlearns addiction patterns (Bleyer: 2017). 

This theory is supported by brain imaging techniques that display how LSD decreases communication between the brain regions that create the Default Mode Network (DMN), a collection of brain areas that control and repress consciousness. When under LSD, researchers have demonstrated how the DMN disintegrates, allowing for an increase in communication between normally segregated brain networks, something that has been associated with more fluid modes of cognition, or clearer thoughts (Carhart-Harrs: 2016). To properly understand the real mechanisms behind its efficacy however, further research is currently underway, as well as modern trials combining LSD with psychotherapeutic practices (MAPS: 2019). 

To conclude, as attitudes towards the cause of addiction are changing- from being caused by substances to being caused by existential crises, attitudes towards treatments are changing too. LSD has a strong historical record in aiding with the condition and, coupled with emerging data from new studies further supporting, and refining its utility, it is showing promising signs of becoming an effective treatment for addiction. 
 

Sources 

 

Taub, Benjamin: The Third Wave 

Bleyer, Jennifer: Psychology Today 

Krebs, TS. et al. : Pub Med

Chant, Ian: Scientific American

MAPS 

Carhart-Harris RL. et al. : Beckley Foundation 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
APR 22, 2020
Drug Discovery & Development
APR 22, 2020
Only 3% of COVID-19 Antibody Tests Approved by FDA
So far, only 3% of at least 90 COVID-19 antibody tests in the US have been approved by the Food and Drug Administration ...
APR 24, 2020
Drug Discovery & Development
APR 24, 2020
Teenage Cannabis Use May Prime the Brain to Enjoy Cocaine
New research has found that teenage cannabis use may make the brain more susceptible to the effects of cocaine. "It ...
APR 30, 2020
Drug Discovery & Development
APR 30, 2020
Shortcuts in Drug Development may Cause Long Term Damage
   
MAY 04, 2020
Immunology
MAY 04, 2020
GeoVax and Sino Bio Collaborate on COVID-19 Vaccine Work
GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and ...
MAY 09, 2020
Cancer
MAY 09, 2020
Examining a Combination Therapy Against Gastric Cancer
Often when it comes to treatments for cancer, designing or discovering new leads can take years. One of the common pract ...
MAY 08, 2020
Drug Discovery & Development
MAY 08, 2020
Cholesterol Drugs May Boost Healthy Gut Bacteria in Obese People
While statins have long been known for their efficacy in treating high cholesterol, until recently, there was no evidenc ...
Loading Comments...